Cargando…

Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models

Facioscapulohumeral muscular dystrophy (FSHD) is caused by misexpression of DUX4 in skeletal myocytes. As DUX4 is the key therapeutic target in FSHD, surrogate biomarkers of DUX4 expression in skeletal muscle are critically needed for clinical trials. Although no natural animal models of FSHD exist,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nunes, Andreia M., Ramirez, Monique, Jones, Takako I., Jones, Peter L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Company of Biologists Ltd 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405850/ https://www.ncbi.nlm.nih.gov/pubmed/34338285 http://dx.doi.org/10.1242/dmm.049016

Ejemplares similares

A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy
por: Jones, Takako, et al.
Publicado: (2018)

Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy
por: Himeda, Charis L., et al.
Publicado: (2018)

DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2020)

Transgenic Drosophila for Investigating DUX4 and FRG1, Two Genes Associated with Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Jones, Takako I., et al.
Publicado: (2016)

Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7
por: Banerji, Christopher R S, et al.
Publicado: (2021)

Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity
por: Jones, Takako I., et al.
Publicado: (2020)

Influence of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Possible Treatments
por: Duranti, Elisa, et al.
Publicado: (2023)

Identification of Serum Interleukin 6 Levels as a Disease Severity Biomarker in Facioscapulohumeral Muscular Dystrophy
por: Gros, Marilyn, et al.
Publicado: (2022)

Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics
por: Chen, Jennifer CJ, et al.
Publicado: (2016)

Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy
por: Saad, Nizar Y., et al.
Publicado: (2021)

A Deoxyribonucleic Acid Decoy Trapping DUX4 for the Treatment of Facioscapulohumeral Muscular Dystrophy
por: Mariot, Virginie, et al.
Publicado: (2020)

Telomere Position Effect (TPE) Regulates DUX4 in Human Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Stadler, Guido, et al.
Publicado: (2013)

p53-independent DUX4 pathology in cell and animal models of facioscapulohumeral muscular dystrophy
por: Bosnakovski, Darko, et al.
Publicado: (2017)

Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy
por: Bouwman, Linde F., et al.
Publicado: (2021)

CRISPR mediated targeting of DUX4 distal regulatory element represses DUX4 target genes dysregulated in Facioscapulohumeral muscular dystrophy
por: Das, Sunny, et al.
Publicado: (2021)

Antagonism Between DUX4 and DUX4c Highlights a Pathomechanism Operating Through β-Catenin in Facioscapulohumeral Muscular Dystrophy
por: Ganassi, Massimo, et al.
Publicado: (2022)

A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy
por: Feng, Qing, et al.
Publicado: (2015)

DUX4 promotes transcription of FRG2 by directly activating its promoter in facioscapulohumeral muscular dystrophy
por: Thijssen, Peter E, et al.
Publicado: (2014)

Adenine base editing of the DUX4 polyadenylation signal for targeted genetic therapy in facioscapulohumeral muscular dystrophy
por: Šikrová, Darina, et al.
Publicado: (2021)

Multiple Protein Domains Contribute to Nuclear Import and Cell Toxicity of DUX4, a Candidate Pathogenic Protein for Facioscapulohumeral Muscular Dystrophy
por: Corona, Edgardo Daniel, et al.
Publicado: (2013)

A Targeted Approach for Evaluating DUX4-Regulated Proteins as Potential Serum Biomarkers for Facioscapulohumeral Muscular Dystrophy Using Immunoassay Proteomics
por: Campbell, Amy E., et al.
Publicado: (2023)

Multi-Omics Identifies Circulating miRNA and Protein Biomarkers for Facioscapulohumeral Dystrophy
por: Heier, Christopher R., et al.
Publicado: (2020)

Identification of circulating miRNAs differentially expressed in patients with Limb-girdle, Duchenne or facioscapulohumeral muscular dystrophies
por: García-Giménez, José Luis, et al.
Publicado: (2022)

A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4
por: Sasaki-Honda, Mitsuru, et al.
Publicado: (2018)

Treatment of facioscapulohumeral muscular dystrophy with Denosumab
por: Lefkowitz, Stanley S., et al.
Publicado: (2012)

Sarcopenic Obesity in Facioscapulohumeral Muscular Dystrophy
por: Vera, Kathryn, et al.
Publicado: (2020)

Characterizing the face in facioscapulohumeral muscular dystrophy
por: Loonen, T. G. J., et al.
Publicado: (2020)

The socioeconomic burden of facioscapulohumeral muscular dystrophy
por: Blokhuis, Anna M., et al.
Publicado: (2021)

Baroreflex sensitivity in facioscapulohumeral muscular dystrophy
por: Anselmo, Miguel, et al.
Publicado: (2022)

UK Facioscapulohumeral Muscular Dystrophy (FSHD) Patient Registry
por: Wood, Libby, et al.
Publicado: (2014)

RIPK3‐mediated cell death is involved in DUX4‐mediated toxicity in facioscapulohumeral dystrophy
por: Mariot, Virginie, et al.
Publicado: (2021)

Elderly Onset of Weakness in Facioscapulohumeral Muscular Dystrophy
por: Fee, Dominic B.
Publicado: (2012)

Upper Girdle Imaging in Facioscapulohumeral Muscular Dystrophy
por: Tasca, Giorgio, et al.
Publicado: (2014)

Facioscapulohumeral muscular dystrophy: Are telomeres the end of the story?
por: Stadler, Guido, et al.
Publicado: (2013)

Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy
por: Greco, Anna, et al.
Publicado: (2020)

Cellular and animal models for facioscapulohumeral muscular dystrophy
por: DeSimone, Alec M., et al.
Publicado: (2020)

Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy
por: Bittel, Adam J., et al.
Publicado: (2020)

Genetic Approaches for the Treatment of Facioscapulohumeral Muscular Dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2021)

Cognitive profile of patients with facioscapulohumeral muscular dystrophy
por: dos Santos, Vanessa Brzoskowski, et al.
Publicado: (2021)

Cardiac Involvement in Facioscapulohumeral Muscular Dystrophy (FSHD)
por: Ducharme-Smith, Allison, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_95mio63aqqvpr09r42ct4jds1h